Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Subscribe

Sci. Signal., 24 February 2009
Vol. 2, Issue 59, p. re1
[DOI: 10.1126/scisignal.259re1]

REVIEWS

Positive and Negative Modulation of Angiogenesis by VEGFR1 Ligands

Yihai Cao*

Department of Microbiology, Tumor and Cell Biology, Karolinska Institute, 171 77 Stockholm, Sweden.

Abstract: Vascular endothelial growth factor–A (VEGF-A) is a key target for new antiangiogenic drugs for the treatment of both malignant and nonmalignant human diseases. Vascular effects of VEGF family members are mainly mediated by VEGF receptor 2 (VEGFR2). Conversely, the function and signaling of VEGFR1, which is present on endothelial and nonendothelial cells, are poorly understood. Intriguingly, two of five members in the VEGF family—VEGF-B and placental growth factor (PlGF)—are exclusive ligands for VEGFR1 and do not interact with the other VEGFRs, VEGFR2 and VEGFR3. These VEGFR1-specific ligands may be important therapeutic targets for the treatment of cancer. This review discusses the distinctive roles of VEGFR1 and its ligands PlGF and VEGF-B in the mediation of angiogenic signaling and considers the therapeutic potential of targeting these particular vascular factors.

* Corresponding author. E-mail, yihai.cao{at}ki.se

Citation: Y. Cao, Positive and Negative Modulation of Angiogenesis by VEGFR1 Ligands. Sci. Signal. 2, re1 (2009).

Read the Full Text


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Vascular endothelial growth factor-dependent spatiotemporal dual roles of placental growth factor in modulation of angiogenesis and tumor growth.
X. Yang, Y. Zhang, Y. Yang, S. Lim, Z. Cao, J. Rak, and Y. Cao (2013)
PNAS 110, 13932-13937
   Abstract »    Full Text »    PDF »
Anti-VEGF- and anti-VEGF receptor-induced vascular alteration in mouse healthy tissues.
Y. Yang, Y. Zhang, Z. Cao, H. Ji, X. Yang, H. Iwamoto, E. Wahlberg, T. Lanne, B. Sun, and Y. Cao (2013)
PNAS 110, 12018-12023
   Abstract »    Full Text »    PDF »
The Basis for the Distinct Biological Activities of Vascular Endothelial Growth Factor Receptor-1 Ligands.
A. Anisimov, V.-M. Leppanen, D. Tvorogov, G. Zarkada, M. Jeltsch, T. Holopainen, S. Kaijalainen, and K. Alitalo (2013)
Science Signaling 6, ra52
   Abstract »    Full Text »    PDF »
VEGFR1 and NRP1 Endothelial Expressions Predict Distant Relapse after Radical Prostatectomy in Clinically Localized Prostate Cancer.
M. TALAGAS, A. UGUEN, R. GARLANTEZEC, G. FOURNIER, L. DOUCET, E. GOBIN, P. MARCORELLES, A. VOLANT, and M. DE BRAEKELEER (2013)
Anticancer Res 33, 2065-2075
   Abstract »    Full Text »    PDF »
Tumor cell-derived placental growth factor sensitizes antiangiogenic and antitumor effects of anti-VEGF drugs.
E.-M. E. Hedlund, X. Yang, Y. Zhang, Y. Yang, M. Shibuya, W. Zhong, B. Sun, Y. Liu, K. Hosaka, and Y. Cao (2013)
PNAS 110, 654-659
   Abstract »    Full Text »    PDF »
Endothelial Differentiation of SHED Requires MEK1/ERK Signaling.
L. W. Bento, Z. Zhang, A. Imai, F. Nor, Z. Dong, S. Shi, F. B. Araujo, and J. E. Nor (2013)
Journal of Dental Research 92, 51-57
   Abstract »    Full Text »    PDF »
Overcoming Resistance to Antiangiogenic Therapies.
S. Tejpar, H. Prenen, and M. Mazzone (2012)
Oncologist 17, 1039-1050
   Abstract »    Full Text »    PDF »
Mesenchymal stromal cells orchestrate follicular lymphoma cell niche through the CCL2-dependent recruitment and polarization of monocytes.
F. Guilloton, G. Caron, C. Menard, C. Pangault, P. Ame-Thomas, J. Dulong, J. De Vos, D. Rossille, C. Henry, T. Lamy, et al. (2012)
Blood 119, 2556-2567
   Abstract »    Full Text »    PDF »
{beta}-Hairpin Peptide That Targets Vascular Endothelial Growth Factor (VEGF) Receptors: DESIGN, NMR CHARACTERIZATION, AND BIOLOGICAL ACTIVITY.
D. Diana, A. Basile, L. De Rosa, R. Di Stasi, S. Auriemma, C. Arra, C. Pedone, M. C. Turco, R. Fattorusso, and L. D. D'Andrea (2011)
J. Biol. Chem. 286, 41680-41691
   Abstract »    Full Text »    PDF »
Bevacizumab Treatment for Advanced Breast Cancer.
R. H. Alvarez, V. Guarneri, F. Icli, S. Johnston, D. Khayat, S. Loibl, M. Martin, C. Zielinski, P. Conte, and G. N. Hortobagyi (2011)
Oncologist 16, 1684-1697
   Abstract »    Full Text »    PDF »
Expression of a functional VEGFR-1 in tumor cells is a major determinant of anti-PlGF antibodies efficacy.
J. Yao, X. Wu, G. Zhuang, I. M. Kasman, T. Vogt, V. Phan, M. Shibuya, N. Ferrara, and C. Bais (2011)
PNAS 108, 11590-11595
   Abstract »    Full Text »    PDF »
The Biflavonoid Amentoflavone Inhibits Neovascularization Preventing the Activity of Proangiogenic Vascular Endothelial Growth Factors.
V. Tarallo, L. Lepore, M. Marcellini, F. Dal Piaz, L. Tudisco, S. Ponticelli, F. W. Lund, P. Roepstorff, A. Orlandi, C. Pisano, et al. (2011)
J. Biol. Chem. 286, 19641-19651
   Abstract »    Full Text »    PDF »
Structural and biochemical studies of human lysine methyltransferase Smyd3 reveal the important functional roles of its post-SET and TPR domains and the regulation of its activity by DNA binding.
S. Xu, J. Wu, B. Sun, C. Zhong, and J. Ding (2011)
Nucleic Acids Res. 39, 4438-4449
   Abstract »    Full Text »    PDF »
Computational discrete models of tissue growth and regeneration.
F. Azuaje (2011)
Brief Bioinform 12, 64-77
   Abstract »    Full Text »    PDF »
VEGF receptor signaling links inflammation and tumorigenesis in colitis-associated cancer.
M. J. Waldner, S. Wirtz, A. Jefremow, M. Warntjen, C. Neufert, R. Atreya, C. Becker, B. Weigmann, M. Vieth, S. Rose-John, et al. (2010)
J. Exp. Med. 207, 2855-2868
   Abstract »    Full Text »    PDF »
Complement-mediated inhibition of neovascularization reveals a point of convergence between innate immunity and angiogenesis.
H. F. Langer, K.-J. Chung, V. V. Orlova, E. Y. Choi, S. Kaul, M. J. Kruhlak, M. Alatsatianos, R. A. DeAngelis, P. A. Roche, P. Magotti, et al. (2010)
Blood 116, 4395-4403
   Abstract »    Full Text »    PDF »
Do Anti-angiogenic or Angiogenic Factors Contribute to the Protection of Birth Weight at High Altitude Afforded by Andean Ancestry?.
R. D. Davila, C. G. Julian, M. J. Wilson, V. A. Browne, C. Rodriguez, A. W. Bigham, M. D. Shriver, E. Vargas, and L. G. Moore (2010)
Reproductive Sciences 17, 861-870
   Abstract »    PDF »
Wake-up call for endothelial cells.
Y. Cao (2010)
Blood 115, 2336-2337
   Full Text »    PDF »
A Placental Growth Factor Variant Unable to Recognize Vascular Endothelial Growth Factor (VEGF) Receptor-1 Inhibits VEGF-Dependent Tumor Angiogenesis via Heterodimerization.
V. Tarallo, L. Vesci, O. Capasso, M. T. Esposito, T. Riccioni, L. Pastore, A. Orlandi, C. Pisano, and S. De Falco (2010)
Cancer Res. 70, 1804-1813
   Abstract »    Full Text »    PDF »
VEGFR1-mediated pericyte ablation links VEGF and PlGF to cancer-associated retinopathy.
R. Cao, Y. Xue, E.-M. Hedlund, Z. Zhong, K. Tritsaris, B. Tondelli, F. Lucchini, Z. Zhu, S. Dissing, and Y. Cao (2010)
PNAS 107, 856-861
   Abstract »    Full Text »    PDF »
Malignant cell-derived PlGF promotes normalization and remodeling of the tumor vasculature.
E.-M. Hedlund, K. Hosaka, Z. Zhong, R. Cao, and Y. Cao (2009)
PNAS 106, 17505-17510
   Abstract »    Full Text »    PDF »

To Advertise     Find Products


Science Signaling. ISSN 1937-9145 (online), 1945-0877 (print). Pre-2008: Science's STKE. ISSN 1525-8882